Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement

Figure 1

Crohn’s disease activity index (CDAI) scores before and at 12 and 52 weeks after the start of adalimumab (ADA) therapy.